TY - JOUR
T1 - Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
AU - on behalf of the ALLFTD Consortium
AU - Saloner, Rowan
AU - Staffaroni, Adam M.
AU - Dammer, Eric B.
AU - Johnson, Erik C.B.
AU - Paolillo, Emily W.
AU - Wise, Amy
AU - Heuer, Hilary W.
AU - Forsberg, Leah K.
AU - Lario-Lago, Argentina
AU - Webb, Julia D.
AU - Vogel, Jacob W.
AU - Santillo, Alexander F.
AU - Hansson, Oskar
AU - Kramer, Joel H.
AU - Miller, Bruce L.
AU - Li, Jingyao
AU - Loureiro, Joseph
AU - Sivasankaran, Rajeev
AU - Worringer, Kathleen A.
AU - Seyfried, Nicholas T.
AU - Yokoyama, Jennifer S.
AU - Spina, Salvatore
AU - Grinberg, Lea T.
AU - Seeley, William W.
AU - VandeVrede, Lawren
AU - Ljubenkov, Peter A.
AU - Bayram, Ece
AU - Bozoki, Andrea
AU - Brushaber, Danielle
AU - Considine, Ciaran M.
AU - Day, Gregory S.
AU - Dickerson, Bradford C.
AU - Domoto-Reilly, Kimiko
AU - Faber, Kelley
AU - Galasko, Douglas R.
AU - Gendron, Tania
AU - Geschwind, Daniel H.
AU - Ghoshal, Nupur
AU - Graff-Radford, Neill
AU - Hales, Chadwick M.
AU - Honig, Lawrence S.
AU - Hsiung, Ging Yuek R.
AU - Huey, Edward D.
AU - Kornak, John
AU - Kremers, Walter
AU - Lapid, Maria I.
AU - Lee, Suzee E.
AU - Litvan, Irene
AU - Pascual, Belen
AU - Masdeu, Joseph
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature America, Inc. 2025.
PY - 2025
Y1 - 2025
N2 - The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. Here we leveraged aptamer-based proteomics (>4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations (C9orf72, GRN and MAPT) compared with 39 non-carrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN) and extracellular matrix (particularly in MAPT) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of (1) sporadic progressive supranuclear palsy-Richardson syndrome and (2) frontotemporal dementia spectrum clinical syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. ‘Hub’ proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets.
AB - The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. Here we leveraged aptamer-based proteomics (>4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations (C9orf72, GRN and MAPT) compared with 39 non-carrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN) and extracellular matrix (particularly in MAPT) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of (1) sporadic progressive supranuclear palsy-Richardson syndrome and (2) frontotemporal dementia spectrum clinical syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. ‘Hub’ proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets.
UR - http://www.scopus.com/inward/record.url?scp=105005430750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105005430750&partnerID=8YFLogxK
U2 - 10.1038/s43587-025-00878-2
DO - 10.1038/s43587-025-00878-2
M3 - Article
AN - SCOPUS:105005430750
SN - 2662-8465
JO - Nature Aging
JF - Nature Aging
M1 - 9161
ER -